Printing Tumors for Profit

It looked like a piece of candy. May 16, 2024 [WEBSITE]( | [UNSUBSCRIBE]( I was feeling fine until he pulled out the tumor. Printing Tumors for Profit CHRIS CAMPBELL Dear Reader, When I walked into the lab, Adi was printing an ear. “What do you mean you’re printing an ear?” I asked. “Exactly what it sounds like.” He smiled. Turns out, he was using actual skin cells to print an entire ear. Made of skin. An ear. … … … He was printing human skin into an ear. At first, I didn’t believe he was telling me what I thought he was telling me. It sounds like a creepy sci-fi A24 film. But, in fact, Adi is on the bleeding-edge of biotech. Let’s back up. Meet Adi Earlier this year, I met Adi Díaz Nocera, an entrepreneur from Argentina who founded Life SI, a pioneering 3D bioprinting company. Adi and his team have developed a technology that uses real patient cells to create biological tissue, opening up a world of possibilities for personalized medicine and life-saving treatments. Craziest part, it looks like a standard 3D printer. Fortunately, my friend Xenofon took pictures. 3D bioprinting is a process where living cells are deposited layer by layer to create complex tissues and organs. Unlike traditional 3D printing, which uses plastic or metal, bioprinting uses bio-inks made from real patient cells. This allows for the creation of biological structures that can mimic the functionality of human tissues. "We started by developing 3D bioprinters," he said, gesturing towards the machine. "These printers use a syringe charged with real patient cells instead of traditional materials like plastic or polymers. This allows us to create biological tissue through 3D printing technology." URGENT: $6 Biotech Stock Ready to Trade The biggest winner of the AI wealth window won’t be energy, financials, or even big tech… It will be the $12 TRILLION industry that is healthcare. And this tiny biotech stock could be at the top. [Click here now for the details.]( It Puts the Lotion on the Skin One of the first major applications of bioprinted human skin is in the cosmetic industry. The team developed bioprinted human skin, which can be used to test cosmetics, eliminating the need for animal testing. Not only would this eliminate the need to torture animals, it also provides more accurate results for human applications. (Human skin, after all, behaves differently than animal tissue when exposed to various substances.) Adi laid out other applications, like the ability for surgeons to prepare for a complex operation on a patient with a unique tumor. Traditionally, the surgeon would rely on 2D scans and perhaps some rudimentary 3D models to plan the procedure. But with LifeSI's technology, they can now print an exact replica of the patient's tumor, complete with cancerous cells, allowing for a practice run before the actual surgery. This not only increases the chances of a successful operation but also significantly reduces the risk to the patient. And Then He Pulled Out the Tumor Life SI has also begun exploring the use of bioprinted tissues for drug testing. In conventional drug development, new medications are tested on animals or simplified cell cultures. These methods, while useful, often fail to capture the complexity of human biology. Life SI’s approach is different. By using bioprinted tissues made from patient cells, they can test the effectiveness of drugs in a more accurate and personalized manner. This means that treatments can be tailored to individual patients, enhancing their power and minimizing side effects. For example, here’s an actual 3D printed tumor. Using this, you can test drugs before you treat the human with that exact tumor. But Life SI's ambitions extend far beyond creating anatomical models. Their ultimate goal? To create fully functional organs for transplantation using a patient's own cells, eliminating the risk of rejection. Playing God? Such work does not come without its challenges. The notion of bioprinting organs raises ethical questions. Critics argue that it is a form of playing God, interfering with natural processes. Adi, however, sees it differently. He believes that it’s cruel to deny people access to life-saving technologies. For him, the true ethical breach is in allowing preventable deaths to continue when the technology to save lives exists. Of course, there are also practical challenges. Creating functional organs is a complex process that requires not just bioprinting but also understanding how to integrate these organs into the human body. The path to clinical implementation is fraught with regulatory hurdles, technical difficulties, and the need for extensive testing. Yet, LifeSI’s progress so far suggests that these are not insurmountable. Adi sees bioprinting as a paradigm shift in medicine. By combining the precision of 3D printing with the complexity of biology, Life SI is creating a future where healthcare is personalized, accessible, and incredibly advanced. Look, bioprinting is cool. Unfortunately, there aren’t many easy ways to invest. The good news: James just stumbled upon another opportunity in biotech -- a tiny public company using AI to target cancer. AI Meets Biotech Recently, James was talking to our colleague Ray Blanco about companies using AI in biotech. In short, Ray believes he’s hit a goldmine. Here’s the bullet points of the conversation: - A tiny company has been harnessing artificial intelligence to revolutionize drug design with remarkable success. (Despite the naysayers.) - Successful collaborations with major pharma companies have led to HUGE investments and potential billion-dollar milestone payments. - With a strong cash position and groundbreaking clinical trial outcomes, this company’s stock could see a huge run in as little as a couple of weeks. Best part? We haven’t seen anyone -- except Ray -- talking about this company’s stock. It’s flying way under the radar. James just recorded a video giving his take. See what he thinks: [Click to hear what James thinks of this stock.]( Until next time, Chris Campbell For Altucher Confidential Rate this email Like Dislike Thanks for rating this content! Looks like something went wrong. Please try to rate again. Urgent: Claim Your Copy Of This New Book From America’s #1 Retirement Expert! Forget everything you’ve ever been told about retirement. According to [this new book]( – written by America’s #1 retirement expert – you don’t have to wait until you’re 65+… and you don’t need millions of dollars. [The strategy you’ll find outlined inside this book]( is completely different… All you have to do is tap into the little-known income streams revealed inside this book… And you’ll learn exactly how you can generate almost effortless income every month… instantly, in some cases! [And today, for a limited only, you have the chance to claim a copy of this book for just $1. Click here now to claim your special book offer.]( You Might be Interested in... [Executive order: US starts testing first step toward total government control.]( [Gold in Fear, Silver in Greed, Uranium for Easy Money: Rick Rule]( [Pre-Election Swap. Mark THIS date on your calendar!]( ☰ ⊗ [ARCHIVE]( [ABOUT]( [Contact Us]( © 2024 Paradigm Press, LLC. 1001 Cathedral Street, Baltimore, MD 21201. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your Altucher Confidential e-mail subscription and associated external offers sent from Altucher Confidential, feel free to [click here.]( Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@altucherconfidential.com. This address is for feedback only. For questions about your account or to speak with customer service, [contact us here]( or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Altucher Confidential is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our [Privacy Statement.]( If you are having trouble receiving your Altucher Confidential subscription, you can ensure its arrival in your mailbox by [whitelisting Altucher Confidential.](